Cerebrospinal fluid tau and β-amyloid in Alzheimer patients, disease controls and an age-matched random sample
- 30 September 2006
- journal article
- research article
- Published by Elsevier in Neurobiology of Aging
- Vol. 27 (9) , 1202-1211
- https://doi.org/10.1016/j.neurobiolaging.2005.06.005
Abstract
No abstract availableKeywords
This publication has 31 references indexed in Scilit:
- Contrasting metabolic impairment in frontotemporal degeneration and early onset Alzheimer's diseaseNeuroImage, 2004
- Cerebrospinal fluid levels of total-tau, phospho-tau and Aβ42 predicts development of Alzheimer's disease in patients with mild cognitive impairmentActa Neurologica Scandinavica, 2003
- Alzheimer's second patient: Johann F. and his familyAnnals of Neurology, 2002
- Cerebrospinal fluid tau in dementia disorders: a large scale multicenter study by a Japanese study groupNeurobiology of Aging, 2002
- Longitudinal study of cerebrospinal fluid levels of tau, Aβ1–40, and Aβ1–42(43) in Alzheimer's disease: A study in JapanAnnals of Neurology, 1998
- Amyloid β protein levels in cerebrospinal fluid are elevated in early‐onset Alzheimer's diseaseAnnals of Neurology, 1994
- SIDAM – A Structured Interview for the diagnosis of Dementia of the Alzheimer type, Multi-infarct dementia and dementias of other aetiology according to ICD-10 and DSM-III-RPsychological Medicine, 1991
- High molecular weight Alzheimer's disease amyloid peptide immunoreactivity in human serum and CSF is an immunoglobulin GBiochemical and Biophysical Research Communications, 1987
- Clinical diagnosis of Alzheimer's diseaseNeurology, 1984
- Immunoglobulin and other proteins in the cerebrospinal fluid of patients with Alzheimer's disease.Journal of Clinical Pathology, 1984